Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Core Insights - Lenivia, a new antibody therapy, is set to reduce osteoarthritis (OA) pain in dogs for three months with a single injection if approved [1] Company Overview - The therapy targets osteoarthritis pain management in dogs, indicating a focus on animal health solutions [1] Industry Implications - The introduction of Lenivia could represent a significant advancement in veterinary medicine, particularly in pain management for pets [1]